

## Company Overview

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

## Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results

May 8 2018, 5:00 PM EDT

## Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business Update

May 2 2018, 4:05 PM EDT

## Navidea Biopharmaceuticals to Present at 2nd Annual NASH Summit

Apr 16 2018, 7:01 AM EDT

## Stock Overview

Symbol	NAVB
Exchange	NYSE American
Shares OS	162,783,979
Market Cap	\$39.07M
Last Price	\$0.24
52-Week	\$0.2102 - \$0.68

05/18/2018 04:10 PM EDT

## Investor Relations

Jed Latkin  
Chief Financial and Operating Officer  
T: 614-973-7490  
[jlatkin@navidea.com](mailto:jlatkin@navidea.com)

## Management Team

### Michael M. Goldberg, M.D.

President and Chief Executive Officer

### Frederick Cope, Ph. D., F.A.C.N., C.N.S.

Senior Vice President and Chief Scientific Officer

### Jed A. Latkin

Chief Financial Officer and Chief Operating Officer

### William Regan

Chief Compliance Officer, Senior Vice President for Global Regulatory and Quality

## Navidea Biopharmaceuticals, Inc.

4995 Bradenton Avenue  
Suite 240  
Dublin, OH 43017

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.